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Abstract
Background: Several studies conducted in areas of medium or low malaria transmission intensity
have found associations between malaria immunity and plasma antibody levels to glutamate rich
protein (GLURP). This study was conducted to analyse if a similar relationship could be
documented in an area of intense malaria transmission.
Methods: A six month longitudinal study was conducted in an area of holoendemic malaria
transmission in north-eastern Tanzania, where the incidence of febrile malaria decreased sharply
by the age of three years, and anaemia constituted a significant part of the malaria disease burden.
Plasma antibodies to glutamate rich protein (GLURP) were analysed and related with protection
against malaria morbidity in models correcting for the effect of age.
Results: The risk of febrile malaria episodes was reduced significantly in children with measurable
anti-GLURP IgG1 antibodies at enrolment [adjusted odds ratio: 0.39 (95% CI: 0.15, 0.99); P =
0.047]. Interestingly, there was an inverse relationship between the plasma anti-GLURP IgG1 and
IgG3 levels and the levels of parasitaemia at enrolment. However, anti-GLURP IgG2 and IgG4 levels
were not associated with reduction in parasite density. Similarly, antibody levels were not
associated with haemoglobin levels or anaemia risk.
Conclusion:  Cytophilic IgG1 and IgG3 antibodies against R0-GLURP may contribute to the
control of parasite multiplication and reduction in febrile malaria incidence in children living in an
area of intense malaria transmission.
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Background
In areas of stable malaria transmission, immunity is
acquired during childhood [1,2], and the protection is
mainly mediated by antibodies directed against the blood
stages of the parasite [3]. The relationship between
malaria morbidity and antibody levels to malaria antigens
has been analysed in several prospective longitudinal
studies performed in different parts of Africa and Asia [4-
9]. The Glutamate Rich Protein (GLURP) is a Plasmodium
falciparum antigen, which has been studied extensively. It
is a 220 kD protein expressed in the hepatic, asexual and
sexual stages of the parasite life cycle [10]. The protein can
be divided into an N-terminal non-repeat region (R25–500
or R0), a central repeat region (R1) and a C-terminal
repeat region (R2) [11]. GLURP is a malaria vaccine can-
didate, which has undergone phase 1 trials in Europe and
trials are planned to take place in Africa in the near future.
Several immuno-epidemiological studies using sera and
clinical data from various sites have consistently identi-
fied high anti-R0-GLURP immunoglobulin G (IgG) levels
as significant predictors of protection against high levels
of parasitaemia, and febrile malaria episodes [6,12-16].
The protective antibodies are thought to elicit antibody
dependent cytotoxic inhibition (ADCI) [17] through
binding to the surfaces of merozoites [18]. Most of these
studies have been performed in areas of moderate malaria
transmission where protection against malaria fevers is
achieved in those aged 5–15 years. In this report, plasma
antibody levels to R0-GLURP was measured and related to
malaria morbidity in a village subjected to holoendemic
transmission and entomological inoculation rates exceed-
ing one infectious bite per night [2]. In this community
the incidence of febrile malaria decreases sharply by the
age of three years and anaemia constitutes a significant
part of the malaria disease burden [19]. Antibody levels to
R0-GLURP in two other villages located in areas of mod-
erate and low transmission were measured to compare the
age related acquisition of antibodies in individuals living
under different malaria transmission intensity.
Materials and methods
Study sites and population
A longitudinal malariometric study was carried out in
three villages with different malaria transmission intensity
in the Tanga region, Tanzania, as described in detail else-
where [19]. The villages are situated at varying altitudes,
which in north-eastern Tanzania is a proxy for malaria
transmission intensity [20]. Malariometric surveys were
conducted and blood samples were collected in April, July
and September. Haemoglobin levels were measured using
a HemoCue® photometer (Ångelholm, Sweden) and thick
and thin blood smears for malarial microscopy were pre-
pared. Thereafter, blood was centrifuged to obtain
plasma, which was frozen at -20°C. Local village helpers
and health workers at nearby health facilities performed
passive case detection during the six month study period.
The village helpers were provided with first-line antima-
larial drug (sulphadoxine-pyrimethamine), paracetamol,
microscope slides, blood lancets, treatment charts, febrile
case detection forms and storage boxes. Villagers could
seek treatment at any time from these helpers. Patients
with symptoms of malaria were treated with the first-line
antimalarial drug. If they had severe symptoms or did not
respond adequately to the first-line treatment, they were
referred to a health facility. Prior to treatment, the village
helpers collected clinical information and a malaria blood
smear. At each nearby health facility, two permanent staff
members monitored study participants seeking medical
treatment at the facility. If study participants presented at
the facility with a history of fever, a form was completed
and a blood smear collected. Active febrile case detection
was undertaken once per month by the research team.
During active case detection, study participants were seen
by a trained physician and a blood smear was taken from
all study participants who had reported a history of fever
within two days and/or had axillary temperature ≥
37.5°C.
Case definitions and selection of plasma samples for 
antibody assays
Febrile malaria episodes were defined as an axillary tem-
perature ≥ 37.5°C and/or a history of fever within the pre-
vious 48 hours in the presence of asexual P. falciparum
parasites ≥ 5000 parasites/µl [19]. Anaemia was defined as
haemoglobin < 11.0 g/dl [21].
The incidence of febrile malaria episodes was low in Mag-
amba and Ubiri [19]. In Mgome, 219 of the 254 individ-
uals completed the longitudinal follow-up and from 171
of these individuals, sufficient plasma was available to
measure R0-GLURP IgG class and subclass levels. Thus,
antibody levels were measured in 9, 24, 33, 52, 35, and 18
individuals belonging to the 0–11 months, 1–2 years, 3–
4 years, 5–9 years, 10–14 years, and 15–19 years age
groups, respectively. Of the 171 individuals, 54 had
febrile malaria episodes and 44 developed anaemia dur-
ing the follow-up period.
To compare age-specific acquisition of R0-GLURP IgG
class antibodies in areas of different endemicity, plasma
samples of 40 individuals from Ubiri village (moderate
transmission) and Magamba village (low transmission)
were also tested. The samples were selected randomly
from asymptomatic individuals to represent four age
groups (0–4, 5–9, 10–14 and 15–19 years, N = 10 in each
group). Since malaria morbidity was low in Ubiri and
Magamba, no attempt was made to relate morbidity and
anti-R0-GLURP IgG levels in these villages.Malaria Journal 2005, 4:48 http://www.malariajournal.com/content/4/1/48
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Antibody assays
Antibodies to R0-GLURP were measured by enzyme-
linked immunosorbent assay (ELISA) based on a protocol
developed by Afro Immunoassay. Briefly, microtitre plates
(Maxisorp Nunc, Roskilde, Denmark) were coated over-
night at 4°C with purified his-tag produced recombinant
R0-GLURP (0.5 µg/ml) diluted in phosphate buffered
saline (PBS). The plates were blocked with 3% powdered-
milk-containing-phosphate buffer for one hour. Plasma
from samples diluted 1:200 in dilution buffer (PBS with
1% powdered-milk and 0.1% Tween-20) was added in
duplicate. The plates were then incubated at room tem-
perature for one hour, where after peroxidase-conjugated
rabbit anti-human IgG or IgM (Dako, Glostrup, Den-
mark) was added. Plates were washed four times with
washing buffer (PBS with 0.1% Tween-20 and 0.5 M
NaCl) between steps. Colour was developed using hydro-
gen peroxide with O-phenylenediamine (Dako, Glostrup,
Denmark), and reading of antibody absorbance was done
at 492 nm. Samples were retested if the measured differ-
ences in absorbance values between duplicate samples
were higher than 15%. For determination of IgG sub-
classes (IgG1, IgG2, IgG3 and IgG4), plasma samples
diluted 1:50 were added in duplicate and incubated for
one hour at room temperature. The following mono-
clonal mouse anti-human subclasses were used: clone
NL16 for IgG1 (Sky lab), clone NP6002 for IgG2 (Sigma),
clone ZG4 for IgG3 (Sky lab) and clone RJ4 for IgG4 (Sky
lab). The monoclonal IgG subclasses were diluted 1:2000
for IgG1, 1:3000 for IgG2, IgG3 and IgG4 in dilution
buffer and incubated for one hour at room temperature.
Goat anti-mouse IgG conjugated to peroxidase (Caltag)
diluted 1:3000 in dilution buffer was then added and
plates incubated for one hour. Colour development and
reading of antibody absorbance was done as described
above. Antibody levels were measured relative to the titra-
tion of IgG and IgG1-4 standard solutions. Plasma sam-
ples from 31 adult healthy Danes without any previous
exposure to malaria were used as negative controls to gen-
erate cut-off values, which was defined as mean plus two
standard deviations for the respective IgG class or sub-
classes. A positive control containing a pool of plasma
from adult Liberian individuals (kindly provided by Dr. S.
Jepsen, Statens Serum Institut, Copenhagen, Denmark
through Afro Immuno Assay) were tested in parallel to the
study samples. The positive plasma pool contained 27.7,
48.7, 35.7, 18.5, and 46.6 arbitrary units (AU)/ml anti-
R0GLURP antibodies of IgG, IgG1, IgG2, IgG3, and IgG4,
respectively. The cut-off values in arbitrary units were 3.5,
1.4, 1.4, 1.7, and 0 AU/ml for IgG, IgG1, IgG2, IgG3, and
IgG4, respectively. The highest OD values in positive sam-
ples were 2.7 for IgG and 3.8 for IgG1-4.
Data analysis
Data were analysed using Stata/SE version 8.2 (Stata Cor-
poration, Texas, USA; http://www.stata.com). The age
dependence of antibody responses was analyzed by use of
Spearman's rank-order correlation and the mean
matched-pairs test was used to compare R0-GLURP IgG
levels between samples collected at the initiation and at
the end of the study. The Mann-Whitney test was used to
test R0-GLURP IgG class and subclasses levels between
females and males. Univariate and multivariate models
were fitted to estimate to what extent R0-GLURP IgG class
and subclass levels could be attributed to protection
against high parasite density, febrile malaria episodes or
anaemia in individuals from the high transmission vil-
lage. Differences were considered statistically significant if
the 95% confidence interval was not overlapping or P <
0.05.
Results
Plasma antibody levels to R0-GLURP in areas of different 
malaria endemicity
The prevalence and mean levels of anti-R0-GLURP IgG
were highest in residents living under intense and holoen-
demic malaria transmission in Mgome, lower in individ-
uals living under moderate and seasonal transmission in
Ubiri and lowest in residents living under low and unsta-
ble transmission in Magamba (Figure 1). The differences
in IgG levels between these villages were highly significant
(P(z) < 0.001, Trend test). The prevalence and levels of
antibodies increased with donor age in Mgome and Ubiri
villages (Figure 1), although there was a tendency of slight
decrease in antibody levels after the age of 14 years in
Mgome. Antibody levels did not differ significantly
between males and females (Mann-Whitney test Mgome
P(z) = 0.40; Ubiri P(z) = 0.12.; Magamba P(z) = 0.94). In
Mgome, there was no statistical difference in antibody lev-
els between samples collected at the beginning and at the
end of the study (mean difference [95% confidence inter-
val (CI)]: 4.0 arbitrary units (AU) [-15.8, 23.9], P(t) =
0.68, paired T-test). The mean antibody levels were
slightly higher in samples collected at the end of the study
in Ubiri (mean difference [95%CI]: 6.4 AU [-2.1, 15.0],
P(t) = 0.13, paired T-test) and Magamba (mean difference
[95%CI]: 7.6 AU [6.2, 9.0], P(t) < 0.0001, paired T-test).
In all three villages, R0-GLURP IgM was detected at very
low levels with no distinct patterns observed with respect
to age, sex or season (data not shown).
IgG subclass responses to R0-GLURP in Mgome village
The prevalence and mean levels of R0-GLURP IgG anti-
bodies increased with age for all subclasses. For the
cytophilic IgG1 and IgG3, there was a marked increase in
three to four year old children (Figure 2). For the non-
cytophilic IgG2 and IgG4, there was a steady increase inMalaria Journal 2005, 4:48 http://www.malariajournal.com/content/4/1/48
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the levels and proportion of responders throughout the
age groups (Figure 2). The levels of IgG4 antibodies were
generally low.
Relationship between R0-GLURP IgG levels and 
Plasmodium falciparum density in Mgome (high 
transmission village)
Multiple linear regression models adjusting for age were
generated to determine whether the anti-R0-GLURP IgG
levels were associated with P. falciparum density at the ini-
tiation of the study. Interestingly, there was a significant
association between cytophilic IgG subclass antibodies
and reduced parasite density. For IgG1, one log unit
increase in antibodies was associated with a reduction in
P. falciparum density by 1,401 parasites/µl [95% CI: 231,
2571; P = 0.019]; and for IgG3 level, one log unit increase
was associated with a reduction in P. falciparum density at
enrolment by 983 parasites/µl [95% CI: 126, 1841; P =
0.025]. Although similar associations were observed in
univariate analysis for non-cytophilic IgG subclasses such
associations were not significant after adjusting for age
(Table 1).
Relationship between R0-GLURP IgG and risk of 
developing febrile malaria in Mgome
The risk of developing a febrile malaria episode during the
study decreased with age and was 65.2% (43/66), 11.5%
(6/52), 11.4% (4/37) and 5.6% (1/18) for the age groups
0–4, 5–9, 10–14 and 15–19, respectively. Logistic regres-
sion models correcting for age indicated that the presence
Age-specific IgG responses to recombinant R0-GLURP in three villages: Mgome (high malaria transmission), Ubiri (moderate  malaria transmission) and Magamba (low malaria transmission) Figure 1
Age-specific IgG responses to recombinant R0-GLURP in three villages: Mgome (high malaria transmission), Ubiri (moderate 
malaria transmission) and Magamba (low malaria transmission). The levels are presented as arbitrary units on a logarithmic 
scale. Box plots illustrate medians with 25th, 75th and whiskers for 10th and 90th percentiles including outliers (5th/95th percen-
tiles). Lines with filled triangles represent proportion of responders in percentages.
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of a measurable R0-GLURP IgG1 was associated with a
reduced risk of febrile malaria episodes [adjusted odds
ratio (AOR) 0.39 (95% CI: 0.15, 0.99), P = 0.047]. The age
adjusted odds ratio for individuals who had a measurable
IgG3 response was 0.52, but the 95% confidence interval
for this estimate was wide and not significantly different
from one (Table 2). The presence of antibodies to R0-
GLURP of the IgG2 or IgG4 subclasses was not associated
with significant reduction in the risk of febrile malaria
episodes.
Relationship between R0-GLURP IgG and risk of anaemia 
in Mgome
In logistic regression models including age and sex, there
were no statistically significant associations between the
risk of anaemia and having a measurable IgG [AOR: 1.03
(0.45, 2.35); P = 0.95] or IgG subclass (data not shown)
R0-GLURP antibody response. Similarly, in linear regres-
sion models correcting for age and sex, there were no asso-
ciations between plasma R0-GLURP IgG or IgG subclass
levels and the haemoglobin level at enrolment (data not
shown).
Discussion
Studies in which observed clinical protection is linked to
the level of malaria antibodies on an individual level have
been used to identify vaccine targets [5,6,15,22]. In these
types of studies, participants are often divided into suscep-
tible and protected individuals and this obviously
requires that a reasonable number of the participants
Age-specific IgG subclass responses to recombinant R0-GLURP in Mgome (high transmission village) Figure 2
Age-specific IgG subclass responses to recombinant R0-GLURP in Mgome (high transmission village). Panels A, B, C and D rep-
resent IgG1, IgG2, IgG3, and IgG4 subclasses, respectively. The levels are presented as arbitrary units on a logarithmic scale. 
Box plots illustrate medians with 25th, 75th and whiskers for 10th and 90th percentiles including outliers for each IgG subclass. 
Lines with filled triangles represent prevalence of responders in percentages.
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develop clinical symptoms during follow up. To allow
comparisons between immunological parameters, it is
also preferable that the protected individuals are as closely
age matched to the susceptible individuals as possible.
Due to problems of obtaining sufficient amounts of
plasma from infants and young children, most studies
have been conducted in areas of moderate transmission
targeting children between 5–15 years or in areas of high
transmission targeting children over 5 years and adults.
These studies have documented that the presence of R0-
GLURP IgG is associated with protection against febrile
malaria attacks in areas of moderate and seasonal malaria
transmission [6,13-15]. The acquisition of malaria immu-
nity is governed by the transmission intensity [23], and in
areas of holoendemic transmission children of three to
four years of age have already developed considerable
protection against febrile episodes [14,15]. In the current
study, individuals with a measurable anti R0-GLURP IgG1
response had a statistically significant reduction in the risk
of getting a febrile malaria attack compared with those
without such antibodies. The results cannot unravel
whether GLURP antibodies directly were responsible for
the effect or whether they constitute a marker for other
immunological activities. The protection provided by
GLURP antibodies is mainly thought to be mediated
through IgG1 and IgG3 antibodies which dampen the
growth of blood stage parasites by antibody dependent
cellular inhibition (ADCI) [13,14,17,24]; although levels
of IgG2 GLURP antibodies have also been implicated in
protection [13,14]. It is, therefore, of interest that a signif-
icant association between the level of anti R0-GLURP
IgG1 and IgG3 antibodies and the parasite density at
enrolment has been found in this study.
The acquisition of IgG against GLURP was highly depend-
ant on malaria transmission intensity. In the high trans-
mission village antibody levels increased markedly after
the age of two years, and in the three to four years old chil-
dren a very high percentage had a detectable antibodies
response. In the village with moderate transmission anti-
body acquisition was much slower and GLURP antibody
response rates over 50% were only seen in the age groups
older than 10 years.
In areas of high malaria transmission one of the major
disease burdens attributable to P. falciparum infection is
anaemia occurring in infants and young children
[2,19,21]. In Mgome, all children under two years had
haemoglobin levels under 11 g/dl. Thus, it was disap-
pointing that the levels of anti R0-GLURP antibodies were
Table 1: Relationship between P. falciparum density (parasites/µl) and anti R0-GLURP IgG levels (log arbitrary unit/ml) at enrolment.
R0-GLURP antibodies Unadjusted coefficients 
(95% CI)1
P-value Adjusted coefficients (95% 
CI)2
P-value
IgG -773 (-805, 689) 0.378 -146 (-533, 3457) 0.15
IgG1 -2136 (-3477, -795) 0.002 -1401 (-2571, -231) 0.019
IgG2 -1512 (-2894, -128) 0.032 -719 (-2135, 697) 0.318
IgG3 -1482(-2542, -423) 0.006 -983 (-1841, -126) 0.025
IgG4 58 (-590, 706) 0.86 195 (-436, 826) 0.542
1 Univariate linear regression. 2 Multiple linear regressions adjusting for the effect of age including age as square root of age. Models using other 
forms of age correction (age, age × age, log age) gave similar results.
Table 2: Odds ratio for the risk of febrile malaria episodes
R0-GLURP antibodies Unadjusted odds ratio 
(95% CI)1
P-value Adjusted odds ratio (95% 
CI)2
P-value
IgG 0.49 (0.25 – 0.94) 0.031 1.13 (0.50 – 2.53) 0.77
IgG1 0.17 (0.07 – 0.42) <0.001 0.39 (0.15 – 0.99) 0.047
IgG2 0.47 (0.20 – 1.08) 0.075 1.42 (0.58 – 3.46) 0.445
IgG3 0.25 (0.11 – 0.58) 0.001 0.52 (0.20 – 1.40) 0.197
IgG4 0.42 (0.18 – 0.99) 0.046 0.77 (0.30 – 2.03) 0.602
1 Logistic regression indicating risk of febrile malaria episode in individuals with detectable plasma levels of anti R0-GLURP antibodies (for IgG, IgG1, 
IgG2, IgG3 and IgG4, respectively) relative to those without a measurable antibody response. 2 Adjusted for the effect of age including age as square 
root of age.Malaria Journal 2005, 4:48 http://www.malariajournal.com/content/4/1/48
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not associated with haemoglobin levels in multiple linear
regression models or with anaemia in multiple logistic
regression models.
Conclusion
In conclusion, this study conducted in an area of intense
malaria transmission detected an association between
protection against febrile malaria disease and presence of
anti R0-GLURP antibodies and indicated that increasing
levels of antibodies of the IgG1 and the IgG3 subclasses
are associated with a reduction in P. falciparum parasite
densities.
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